More on JAZZ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $250.68 |
|
|||
| Open | $250.13 | ||||
| 52 Wk High | $160.00 | ||||
| 52 Wk Low | $95.80 | ||||
| Day High | $252.50 | ||||
| Day Low | $243.02 | ||||
| P/E | 45.28 | ||||
| EPS | $5.38 | ||||
| Volume | 307,415 | ||||
- Canaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
- Form 144 Jazz Pharmaceuticals Filed by: Iannone Robert
- Jazz Pharmaceuticals prices $1.1B exchangeable notes offering due 2032
- Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals (JAZZ) PT Raised to $277 at RBC Capital
- Jazz Pharmaceuticals (JAZZ) PT Raised to $322 at Morgan Stanley
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at Needham
- Jazz Pharmaceuticals plans $1B note offering and share buyback
- Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals (JAZZ) PT Raised to $281 at Truist Securities
Entities mentioned with JAZZ
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
